mTORC1 Is Involved in Hypoxia-Induced Pulmonary Hypertension Through the Activation of Notch3

Journal of Cellular Physiology

Volumn 229, Issue 12, 2014, Pages 2117-2125

  Wang, Wang ^a   Liu, Jie ^a   Ma, Aiping ^b   Miao, Ran ^a   Jin, Yuling ^a   Zhang, Hongbing ^c   Xu, Kaifeng ^b   Wang, Chen ^a,d   Wang, Jun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c PEKING UNION MEDICAL COLLEGE   (China)

^d BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NOTCH3 RECEPTOR; OXYGEN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTERY MUSCLE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; HYPOXIA; HYPOXIA INDUCED PULMONARY HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; LUNG ARTERY PRESSURE; LUNG PARENCHYMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE;

ANIMALS; ANOXIA; CELL PROLIFERATION; DIPEPTIDES; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MICE; MULTIPROTEIN COMPLEXES; MYOCYTES, SMOOTH MUSCLE; OXYGEN; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84906667178     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24670     Document Type: Article

References (31)

1. Dufner A, Thomas G. 1999. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res 253:100-109.
2. Faber JE, Szymeczek CL, Cotecchia S, Thomas SA, Tanoue A, Tsujimoto G, Zhang H. 2007. Alpha1-adrenoceptor-dependent vascular hypertrophy and remodeling in murine hypoxic pulmonary hypertension. Am J Physiol Heart Circ Physiol 292:H2316-H2323.
3. Fouillade C, Monet-Lepretre M, Baron-Menguy C, Joutel A. 2012. Notch signalling in smooth muscle cells during development and disease. Cardiovasc Res 95:138-146.
4. Gerasimovskaya EV, Tucker DA, Stenmark KR. 2005. Activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin is necessary for hypoxia-induced pulmonary artery adventitial fibroblast proliferation. J Appl Physiol 98:722-731.
5. Ghofrani HA, Voswinckel R, Reichenberger F, Weissmann N, Schermuly RT, Seeger W, Grimminger F. 2006. Hypoxia- and non-hypoxia-related pulmonary hypertension- established and new therapies. Cardiovasc Res 72:30-40.
6. Goncharov DA, Kudryashova TV, Ziai H, Ihida-Stansbury K, DeLisser H, Krymskaya VP, Tuder RM, Kawut SM, Goncharova EA. 2014. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension. Circulation 129:864-874.
7. Houssaini A, Abid S, Mouraret N, Wan F, Rideau D, Saker M, Marcos E, Tissot CM, Dubois-Rande JL, Amsellem V, Adnot S. 2013. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol 48:568-577.
8. Huang H, Zhang P, Wang Z, Tang F, Jiang Z. 2011. Activation of endothelin-1 receptor signaling pathways is associated with neointima formation, neoangiogenesis and irreversible pulmonary artery hypertension in patients with congenital heart disease. Circ J 75:1463-1471.
9. Jin N, Hatton N, Swartz DR, Xia X, Harrington MA, Larsen SH, Rhoades RA. 2000. Hypoxia activates jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. Am J Respir Cell Mol Biol 23:593-601.
10. Khoo JP, Zhao L, Alp NJ, Bendall JK, Nicoli T, Rockett K, Wilkins MR, Channon KM. 2005. Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation 111:2126-2133.
11. Kopan R, Ilagan MX. 2009. The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 137:216-233.
12. Krymskaya VP, Snow J, Cesarone G, Khavin I, Goncharov DA, Lim PN, Veasey SC, Ihida-Stansbury K, Jones PL, Goncharova EA. 2011. MTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J 25:1922-1933.
13. Laplante M, Sabatini DM. 2012. MTOR signaling in growth control and disease. Cell 149:274-293.
14. Lawson ND, Scheer N, Pham VN, Kim CH, Chitnis AB, Campos-Ortega JA, Weinstein BM. 2001. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 128:3675-3683.
15. Li W, Petrimpol M, Molle KD, Hall MN, Battegay EJ, Humar R. 2007. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ Res 100:79-87.
16. Li X, Zhang X, Leathers R, Makino A, Huang C, Parsa P, Macias J, Yuan JX, Jamieson SW, Thistlethwaite PA. 2009. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med 15:1289-1297.
17. Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q, Zha X, Wang F, Wang Y, Jing Y, Zhang S, Chen R, Wang L, Wu E, Cai G, Malinowska-Kolodziej I, Liao Q, Liu Y, Zhao Y, Xu K, Dai J, Han J, Wu L, Zhao RC, Shen H, Zhang H. 2010. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 120:103-114.
18. Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN. 2001. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 163:498-502.
19. Ogawa A, Firth AL, Yao W, Madani MM, Kerr KM, Auger WR, Jamieson SW, Thistlethwaite PA, Yuan JX. 2009. Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 297:L666-L676.
20. Paddenberg R, Stieger P, von Lilien AL, Faulhammer P, Goldenberg A, Tillmanns HH, Kummer W, Braun-Dullaeus, RC. 2007. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res 8:15.
21. Preston IR. 2007. Clinical perspective of hypoxia-mediated pulmonary hypertension. Antioxid Redox Signal 9:711-721.
22. Qiao L, Xie L, Shi K, Zhou T, Hua Y, Liu H. 2012. Notch signaling change in pulmonary vascular remodeling in rats with pulmonary hypertension and its implication for therapeutic intervention. PLoS One 7:e51514.
23. Roca C, Adams RH. 2007. Regulation of vascular morphogenesis by Notch signaling. Genes Dev 21:2511-2524.
24. Semenza GL. 2005. Involvement of hypoxia-inducible factor 1 in pulmonary pathophysiology. Chest 128:592S-594S.
25. Stenmark KR, Fagan KA, Frid MG. 2006. Hypoxia-induced pulmonary vascular remodeling: Cellular and molecular mechanisms. Circ Res 99:675-691.
26. Thistlethwaite PA, Li X, Zhang X. 2010. Notch signaling in pulmonary hypertension. Adv Exp Med Biol 661:279-298.
27. Wang C, Li JF, Zhao L, Liu J, Wan J, Wang YX, Wang J. 2009. Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells. Respir Res 10:123.
28. Wessler JD, Steingart RM, Schwartz GK, Harvey BG, Schaffer W. 2010. Dramatic improvement in pulmonary hypertension with rapamycin. Chest 138:991-993.
29. Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J, Yamazato M, Yuan L, Bradford CN, Shenoy V, Oh SP, Katovich MJ, Raizada MK. 2009. Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension 54:365-371.
30. Yu XM, Wang L, Li JF, Liu J, Li J, Wang W, Wang J, Wang C. 2013. Wnt5a inhibits hypoxia-induced pulmonary arterial smooth muscle cell proliferation by downregulation of beta-catenin. Am J Physiol Lung Cell Mol Physiol 304:L103-L111.
31. Zinzalla V, Stracka D, Oppliger W, Hall MN. 2011. Activation of mTORC2 by association with the ribosome. Cell 144:757-768.